# US 2006/0216713 A1 · Method for the identification of colorectal tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0216713 A1
- Document ID: US20060216713A1
- Status: Published application
- Kind: A1
- Application number: 10/547,669
- Filed: 2004-02-27
- Published: 2006-09-28
- Earliest claimed: 2003-03-07
- Assignees: Istituto Oncologico Romagnolo Cooperativa Sociale a.r.l.
- Inventors: Daniele Calistri; Claudia Rengucci
- Web page: https://patentgrep.com/patent/US20060216713A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Disclosed is a method for the early diagnosis of colorectal carcinoma and determination of pre-cancerous lesions of the colon and rectum based on quantitation of DNA extracted from stool and amplified by PCR techniques.

## Claims

### Claim 1

A method for determining the presence of colorectal tumors or pre-cancerous lesions in a human subject, which comprises:
a) DNA extraction from stool samples
b) PCR amplification of at least three different DNA fragments with a length of 100 base pairs or more, using deoxynucleotide triphosphates or primers labelled with detectable markers;
c) quantitation of the amplified fragments (amplicons);
d) calculation of the total amount of different amplicons;
e) comparison of the values obtained in (d) with a reference value.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the detectable markers used in step (b) are fluorescent molecules.

### Claim 3 (depends on 2)

A method according to claim 2, wherein said fluorescent molecules are selected from HEX, 6-FAM and TAMRA

### Claim 4 (depends on 1)

A method according to claim 1, wherein at least 8 different DNA fragments are amplified in step (b).

### Claim 5 (depends on 1)

A method according to claim 1, wherein the DNA fragments are from 100 to 500 bp.

### Claim 6 (depends on 1)

A method according to claim 1, wherein the DNA fragments span different regions of p53 or APC genes.

### Claim 7 (depends on 6)

A method according to claim 6, wherein p53 fragments corresponding to exons 5-8 are amplified using the following pairs of primers:
a)
ctcttcctgcagtactcccctgc;
gccccagctgctcaccatcgcta;
b)
gattgctcttaggtctggcccctc;
ggccactgacaaccacccttaacc;
c)
gcgttgtctcctaggttggctctg;
caagtggctcctgacctggagtc;
d)
acctgatttccttactgcctctggc;
gtcctgcttgcttacctcgcttagt;

### Claim 8 (depends on 6)

A method according to claim 6, wherein APC fragments are amplified using the following pairs of primers:
a)
aactaccatccagcaacaga;
taatttggcataaggcatag;
b)
cagttgaactctggaaggca;
tgacacaaagactggcttac;
c)
gatgtaatcagacgacacag;
ggcaategaacgactctcaa;
d)
cagtgatcttccagatagcc;
aaatggctcatcgaggctca

### Claim 9 (depends on 1)

A method according to claim 1, wherein the amplicon quantities are interpolated on a calibration curve obtained from known DNA amounts.

### Claim 10 (depends on 1)

A method according to claim 1, wherein the amplicons are quantified with an automatic sequencer/analyser or using fluorimetric, calorimetric, radioactive or spectrophotometric detection systems.

### Claim 11 (depends on 1)

A method according to claim 1, wherein the reference value is determined on the basis of case series comprising healthy subjects and patients affected by colorectal tumor or lesions.

### Claim 12 (depends on 1)

A kit containing oligonucleotides, labelling agents, a thermostable DNA polymerase and user instructions to carry out the method of claim 1.
